| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | -0.21 | 1e-07 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.4 | 8e-07 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.2 | 1e-06 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | -0.21 | 2e-06 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.37 | 2e-06 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.18 | 3e-06 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-06 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.23 | 6e-06 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | -0.17 | 6e-06 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.17 | 7e-06 |